acenocoumarol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anticoagulants, dicoumarol derivatives 48 152-72-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • G 23350
  • G-23350
  • sintrom
  • acenocoumarin
  • nicoumalone
  • acenocoumarol
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
  • Molecular weight: 353.33
  • Formula: C19H15NO6
  • CLOGP: 2.64
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 106.74
  • ALOGS: -4.52
  • ROTB: 5

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.57 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.24 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.28 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.22 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.979 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.296 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 64.417 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.972 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 2.110 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 2.640 % High 1
herg hERG pIC50 4.498 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.549 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.296 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 1.050 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ZAP70 58
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,DDR1,DYRK1B,GRK2,MAPK7,PDK4,STK33,TEK,TTK 12
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 3.475 Moderate 0.77
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 5.483 High 1
mh-clint Mouse hepatocyte intrinsic clearance 4.624 High 1
mppb Mouse plasma protein binding (% unbound) 3.070 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.754 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.77
pppb Pig plasma protein binding (% unbound) 1.870 % High 1
rat-kpuu-brain Rat brain Kpuu 0.083 % Moderate 0.77
rh-clint Rat hepatocyte intrinsic clearance 1.556 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 66.100 % High 1
rppb Rat plasma protein binding (% unbound) 0.990 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 887.156 uM High 1

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 734.96 23.72 395 7667 276058 90344327
International normalised ratio increased 310.83 23.72 127 7935 47189 90573196
Hypocoagulable state 290.97 23.72 58 8004 1541 90618844
Cardiac failure 129.28 23.72 94 7968 109402 90510983
Torsade de pointes 124.88 23.72 48 8014 15134 90605251
Abdominal wall haematoma 117.99 23.72 32 8030 3320 90617065
Acute kidney injury 112.12 23.72 140 7922 320247 90300138
Upper gastrointestinal haemorrhage 112.05 23.72 50 8012 22926 90597459
Haematoma 97.80 23.72 54 8008 38994 90581391
Muscle haemorrhage 90.56 23.72 26 8036 3320 90617065
Hypomagnesaemia 88.53 23.72 49 8013 35539 90584846
Bradycardia 87.77 23.72 67 7995 83780 90536605
Erythrodermic psoriasis 75.88 23.72 18 8044 1088 90619297
Atrial fibrillation 73.45 23.72 74 7988 133537 90486848
Cardio-respiratory arrest 71.72 23.72 53 8009 63087 90557298
Anaemia 68.80 23.72 117 7945 352685 90267700
Retroperitoneal haematoma 68.57 23.72 21 8041 3347 90617038
Hypokalaemia 67.32 23.72 70 7992 131046 90489339
Electrocardiogram QT prolonged 65.25 23.72 53 8009 72403 90547982
Thermohypoaesthesia 64.20 23.72 11 8051 122 90620263
Vascular resistance pulmonary decreased 62.49 23.72 10 8052 70 90620315
Sight disability 62.45 23.72 11 8051 145 90620240
Gingival bleeding 61.85 23.72 29 8033 14874 90605511
Anticoagulation drug level above therapeutic 60.53 23.72 17 8045 2005 90618380
Subdural haematoma 52.91 23.72 27 8035 16618 90603767
Hyponatraemia 52.48 23.72 62 8000 133476 90486909
Lower gastrointestinal haemorrhage 51.98 23.72 22 8040 8870 90611515
Euphoric mood 51.35 23.72 19 8043 5390 90614995
Syncope 51.16 23.72 61 8001 132602 90487783
Gastrointestinal sounds abnormal 50.76 23.72 18 8044 4525 90615860
Haematuria 50.51 23.72 34 8028 34903 90585482
Left-to-right cardiac shunt 49.91 23.72 10 8052 272 90620113
Hyperkalaemia 49.17 23.72 43 8019 64921 90555464
Multimorbidity 46.93 23.72 11 8051 631 90619754
Wound haemorrhage 46.38 23.72 15 8047 2852 90617533
Vessel puncture site haemorrhage 44.52 23.72 8 8054 119 90620266
Respiratory tract infection 44.49 23.72 39 8023 59039 90561346
Amaurosis 44.12 23.72 11 8051 819 90619566
Stupor 43.88 23.72 17 8045 5465 90614920
Right ventricular failure 43.83 23.72 25 8037 19180 90601205
Haemorrhage intracranial 43.61 23.72 23 8039 15139 90605246
Hypocalcaemia 42.42 23.72 33 8029 42335 90578050
Optic ischaemic neuropathy 40.29 23.72 12 8050 1740 90618645
Renal phospholipidosis 39.57 23.72 8 8054 228 90620157
Extensor plantar response 38.22 23.72 11 8051 1416 90618969
Neuromyelitis optica spectrum disorder 37.75 23.72 11 8051 1479 90618906
Dermatitis exfoliative generalised 36.60 23.72 15 8047 5578 90614807
Pupillary reflex impaired 35.88 23.72 12 8050 2533 90617852
Ventricular tachycardia 35.60 23.72 24 8038 24684 90595701
Disorganised speech 35.19 23.72 11 8051 1874 90618511
Cerebral haemorrhage 34.80 23.72 27 8035 34495 90585890
Acute generalised exanthematous pustulosis 34.42 23.72 19 8043 13684 90606701
Parkinsonism 33.96 23.72 19 8043 14046 90606339
Drug reaction with eosinophilia and systemic symptoms 33.75 23.72 29 8033 42729 90577656
Cardiac failure chronic 33.10 23.72 14 8048 5632 90614753
Platelet dysfunction 32.42 23.72 6 8056 106 90620279
Pain 32.24 23.72 25 8037 996316 89624069
Mucocutaneous haemorrhage 32.00 23.72 6 8056 114 90620271
Pyogenic granuloma 31.42 23.72 7 8055 320 90620065
Rash 31.21 23.72 16 8046 796084 89824301
Haemarthrosis 30.60 23.72 12 8050 3982 90616403
Melaena 30.35 23.72 25 8037 34772 90585613
Colitis microscopic 29.49 23.72 16 8046 11143 90609242
Neurological decompensation 28.53 23.72 11 8051 3490 90616895
Serotonin syndrome 28.50 23.72 25 8037 37862 90582523
Tetany 27.96 23.72 10 8052 2574 90617811
Transaminases increased 26.89 23.72 24 8038 37168 90583217
Acute leukaemia 26.67 23.72 8 8054 1188 90619197
Pulmonary hypertension 26.02 23.72 25 8037 42498 90577887
Metabolic acidosis 25.49 23.72 28 8034 55648 90564737
Ecchymosis 25.35 23.72 15 8047 12308 90608077
Disorientation 25.24 23.72 25 8037 44089 90576296
Subdural haemorrhage 25.23 23.72 10 8052 3413 90616972
Haematemesis 24.86 23.72 22 8040 33704 90586681
Hyperreflexia 24.71 23.72 12 8050 6645 90613740
Conjunctival haemorrhage 23.76 23.72 10 8052 3974 90616411

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 550.43 19.69 428 7547 266571 42346789
International normalised ratio increased 384.99 19.69 185 7790 47983 42565377
Hypocoagulable state 234.69 19.69 51 7924 962 42612398
Haemorrhage intracranial 203.54 19.69 87 7888 17105 42596255
Cardiac failure 87.93 19.69 104 7871 106752 42506608
Hepatic vein dilatation 72.80 19.69 15 7960 216 42613144
Upper gastrointestinal haemorrhage 69.05 19.69 52 7923 30247 42583113
Liver palpable 68.99 19.69 15 7960 283 42613077
Anaemia 68.29 19.69 157 7818 280121 42333239
Haematoma 68.12 19.69 50 7925 27973 42585387
Labelled drug-drug interaction medication error 62.56 19.69 38 7937 15544 42597816
Subdural haematoma 62.45 19.69 44 7931 23094 42590266
Abdominal wall haematoma 60.90 19.69 21 7954 2301 42611059
Melaena 53.92 19.69 50 7925 38696 42574664
Inferior vena cava dilatation 53.91 19.69 15 7960 805 42612555
Ventricular enlargement 51.89 19.69 14 7961 669 42612691
Atrial enlargement 50.99 19.69 14 7961 715 42612645
Hyperkalaemia 49.76 19.69 68 7907 80390 42532970
Epistaxis 46.74 19.69 60 7915 66766 42546594
Acute kidney injury 45.31 19.69 161 7814 367176 42246184
Lower gastrointestinal haemorrhage 45.04 19.69 27 7948 10781 42602579
Retroperitoneal haematoma 41.28 19.69 17 7958 3034 42610326
Fixed eruption 37.77 19.69 15 7960 2439 42610921
Spontaneous haematoma 37.01 19.69 11 7964 747 42612613
Dyspnoea at rest 35.88 19.69 17 7958 4232 42609128
Ejection fraction decreased 35.64 19.69 31 7944 22056 42591304
Cardiac failure chronic 34.94 19.69 22 7953 9579 42603781
Anticoagulation drug level above therapeutic 33.58 19.69 14 7961 2576 42610784
Chest wall haematoma 33.58 19.69 8 7967 230 42613130
Lividity 30.83 19.69 7 7968 162 42613198
Influenza virus test positive 30.47 19.69 7 7968 171 42613189
Gastroduodenal haemorrhage 30.09 19.69 7 7968 181 42613179
Scedosporium infection 29.24 19.69 11 7964 1547 42611813
Rales 29.18 19.69 21 7954 11379 42601981
Haematoma muscle 29.16 19.69 12 7963 2138 42611222
Renal haemorrhage 28.82 19.69 11 7964 1608 42611752
Ventricular tachycardia 27.49 19.69 31 7944 30129 42583231
Oesophageal adenocarcinoma stage 0 26.29 19.69 4 7971 7 42613353
Electrocardiogram PR prolongation 25.98 19.69 9 7966 999 42612361
Immobilisation prolonged 25.05 19.69 4 7971 11 42613349
Haematuria 24.51 19.69 41 7934 57758 42555602
Muscle haemorrhage 24.49 19.69 13 7962 4112 42609248
Atrial tachycardia 24.45 19.69 13 7962 4127 42609233
Coronary artery stenosis 24.04 19.69 18 7957 10361 42602999
Lactic acidosis 21.77 19.69 34 7941 45227 42568133
Breath sounds abnormal 21.61 19.69 18 7957 12075 42601285
Cerebral haemorrhage 21.19 19.69 31 7944 38935 42574425
Orthopnoea 21.19 19.69 13 7962 5404 42607956
Quadrantanopia 20.75 19.69 5 7970 151 42613209
Shock haemorrhagic 20.74 19.69 20 7955 16222 42597138
Subdural haemorrhage 20.69 19.69 11 7964 3490 42609870
Blood cyanide increased 20.41 19.69 4 7971 44 42613316

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 1203.75 18.82 793 15007 499390 110074109
International normalised ratio increased 648.58 18.82 293 15507 86479 110487020
Hypocoagulable state 504.74 18.82 108 15692 2507 110570992
Haemorrhage intracranial 255.30 18.82 110 15690 28859 110544640
Cardiac failure 217.66 18.82 194 15606 187432 110386067
Abdominal wall haematoma 169.16 18.82 53 15747 5652 110567847
Upper gastrointestinal haemorrhage 165.87 18.82 98 15702 49998 110523501
Haematoma 156.86 18.82 100 15700 58376 110515123
Acute kidney injury 147.16 18.82 297 15503 635133 109938366
Anaemia 139.06 18.82 266 15534 546820 110026679
Subdural haematoma 109.48 18.82 67 15733 36387 110537112
Retroperitoneal haematoma 102.42 18.82 37 15763 6094 110567405
Hyperkalaemia 102.27 18.82 111 15689 135685 110437814
Lower gastrointestinal haemorrhage 96.82 18.82 49 15751 18437 110555062
Anticoagulation drug level above therapeutic 85.12 18.82 30 15770 4600 110568899
Torsade de pointes 84.85 18.82 48 15752 22552 110550947
Atrial fibrillation 80.72 18.82 129 15671 229513 110343986
Cardiac failure chronic 79.39 18.82 39 15761 13772 110559727
Hypomagnesaemia 79.08 18.82 67 15733 60303 110513196
Melaena 77.40 18.82 70 15730 68687 110504812
Hepatic vein dilatation 76.01 18.82 15 15785 229 110573270
Haematuria 75.32 18.82 75 15725 82930 110490569
Liver palpable 70.57 18.82 15 15785 336 110573163
Muscle haemorrhage 70.20 18.82 29 15771 6840 110566659
Bradycardia 69.84 18.82 98 15702 155419 110418080
Hypokalaemia 68.97 18.82 106 15694 182342 110391157
Ventricular tachycardia 66.52 18.82 56 15744 49953 110523546
Epistaxis 62.80 18.82 85 15715 130287 110443212
Electrocardiogram QT prolonged 61.78 18.82 77 15723 108883 110464616
Labelled drug-drug interaction medication error 61.40 18.82 43 15757 29259 110544240
Gingival bleeding 60.93 18.82 37 15763 19802 110553697
Vascular resistance pulmonary decreased 57.51 18.82 10 15790 72 110573427
Syncope 56.88 18.82 103 15697 202433 110371066
Erythrodermic psoriasis 56.78 18.82 18 15782 1992 110571507
Stupor 55.59 18.82 26 15774 8239 110565260
Pain 55.53 18.82 34 15766 954921 109618578
Inferior vena cava dilatation 55.46 18.82 15 15785 952 110572547
Ventricular enlargement 54.82 18.82 14 15786 710 110572789
Thermohypoaesthesia 53.54 18.82 10 15790 112 110573387
Ejection fraction decreased 52.77 18.82 45 15755 40835 110532664
Hyponatraemia 50.42 18.82 102 15698 217551 110355948
Spontaneous haematoma 49.01 18.82 16 15784 1945 110571554
Left-to-right cardiac shunt 48.56 18.82 10 15790 191 110573308
Atrial enlargement 48.39 18.82 14 15786 1137 110572362
Joint swelling 48.34 18.82 4 15796 442841 110130658
Sight disability 47.48 18.82 10 15790 214 110573285
Cerebral haemorrhage 46.94 18.82 52 15748 64916 110508583
Cardio-respiratory arrest 46.15 18.82 69 15731 115767 110457732
Mucocutaneous haemorrhage 44.87 18.82 10 15790 281 110573218
Fixed eruption 43.70 18.82 18 15782 4214 110569285
Hypocalcaemia 43.28 18.82 50 15750 65316 110508183
Disorganised speech 40.86 18.82 16 15784 3287 110570212
Haemarthrosis 40.05 18.82 20 15780 7309 110566190
Respiratory tract infection 39.61 18.82 50 15750 71567 110501932
Euphoric mood 39.34 18.82 21 15779 8806 110564693
Chest wall haematoma 38.82 18.82 10 15790 525 110572974
Immobilisation prolonged 38.45 18.82 8 15792 161 110573338
Gastrointestinal sounds abnormal 37.62 18.82 18 15782 6000 110567499
Dyspnoea at rest 37.60 18.82 20 15780 8326 110565173
Hypotension 37.41 18.82 161 15639 523688 110049811
Vessel puncture site haemorrhage 36.76 18.82 8 15792 201 110573298
Rash 36.66 18.82 38 15762 820926 109752573
Arthralgia 36.05 18.82 35 15765 779597 109793902
Angina pectoris 35.26 18.82 44 15756 62251 110511248
Orthopnoea 34.99 18.82 21 15779 11000 110562499
Product dose omission issue 34.84 18.82 3 15797 321779 110251720
Drug intolerance 34.30 18.82 8 15792 406504 110166995
Blood bilirubin increased 32.78 18.82 47 15753 75925 110497574
Wound haemorrhage 32.16 18.82 15 15785 4723 110568776
Renal phospholipidosis 31.63 18.82 8 15792 390 110573109
Pulmonary hypertension 31.24 18.82 39 15761 55181 110518318
Infusion related reaction 31.18 18.82 8 15792 381154 110192345
Nasopharyngitis 30.91 18.82 9 15791 394352 110179147
Disorientation 30.90 18.82 44 15756 70627 110502872
Calciphylaxis 30.74 18.82 14 15786 4173 110569326
Right ventricular failure 30.33 18.82 27 15773 25927 110547572
Extensor plantar response 29.69 18.82 11 15789 1944 110571555
Urticaria 29.56 18.82 5 15795 318852 110254647
Shock haemorrhagic 29.20 18.82 27 15773 27220 110546279
Azotaemia 28.90 18.82 18 15782 10067 110563432
Neuromyelitis optica spectrum disorder 28.55 18.82 10 15790 1505 110571994
Multimorbidity 28.52 18.82 10 15790 1510 110571989
Gastroduodenal haemorrhage 28.49 18.82 7 15793 303 110573196
Mitral valve incompetence 28.17 18.82 29 15771 33300 110540199
Amaurosis 28.08 18.82 10 15790 1579 110571920
Ischaemic stroke 28.05 18.82 32 15768 41231 110532268
International normalised ratio abnormal 27.98 18.82 15 15785 6342 110567157
Blood loss anaemia 27.78 18.82 22 15778 18003 110555496
Oesophageal adenocarcinoma stage 0 27.37 18.82 4 15796 7 110573492
Procedural haemorrhage 27.29 18.82 14 15786 5413 110568086
Scedosporium infection 27.24 18.82 11 15789 2447 110571052
Arrhythmia 27.07 18.82 41 15759 69534 110503965
Chronic kidney disease 26.95 18.82 43 15757 76248 110497251
Electrocardiogram PR prolongation 26.64 18.82 10 15790 1833 110571666
Maternal exposure during pregnancy 25.96 18.82 3 15797 254880 110318619
Renal failure 25.74 18.82 81 15719 226493 110347006
Fatigue 25.43 18.82 89 15711 1215869 109357630
Influenza virus test positive 25.02 18.82 7 15793 504 110572995
Haematoma muscle 24.86 18.82 12 15788 4078 110569421
Atrioventricular block 24.73 18.82 20 15780 16857 110556642
Serotonin syndrome 24.65 18.82 36 15764 59117 110514382
Musculoskeletal stiffness 24.62 18.82 5 15795 279817 110293682
Pyogenic granuloma 24.60 18.82 7 15793 536 110572963
Metabolic acidosis 24.58 18.82 48 15752 99696 110473803
International normalised ratio decreased 24.36 18.82 15 15785 8221 110565278
Inappropriate antidiuretic hormone secretion 24.28 18.82 27 15773 33824 110539675
Abdominal discomfort 24.28 18.82 13 15787 393845 110179654
Ecchymosis 24.26 18.82 20 15780 17318 110556181
Hypersensitivity 23.95 18.82 14 15786 403984 110169515
Coronary artery stenosis 23.84 18.82 18 15782 13740 110559759
Lividity 23.78 18.82 7 15793 604 110572895
Rales 23.62 18.82 23 15777 24716 110548783
Dermatitis exfoliative generalised 22.74 18.82 16 15784 10956 110562543
Swelling 22.51 18.82 11 15789 351030 110222469
Duodenal ulcer 22.21 18.82 20 15780 19494 110554005
Pupillary reflex impaired 22.07 18.82 11 15789 4004 110569495
Colitis microscopic 22.05 18.82 17 15783 13377 110560122
International normalised ratio fluctuation 21.90 18.82 11 15789 4069 110569430
Anxiety 21.85 18.82 11 15789 345067 110228432
Optic ischaemic neuropathy 21.73 18.82 11 15789 4136 110569363
Systemic lupus erythematosus 21.45 18.82 5 15795 254333 110319166
Mixed liver injury 21.36 18.82 16 15784 12063 110561436
Blood cyanide increased 21.24 18.82 4 15796 47 110573452
Congestive cardiomyopathy 21.15 18.82 17 15783 14202 110559297
Sinusitis 21.09 18.82 8 15792 296680 110276819
Infection 20.84 18.82 13 15787 362187 110211312
Gastrointestinal haemorrhage 20.50 18.82 61 15739 165457 110408042
Platelet dysfunction 20.44 18.82 6 15794 513 110572986
Acute generalised exanthematous pustulosis 20.42 18.82 20 15780 21644 110551855
Renal haemorrhage 20.31 18.82 9 15791 2516 110570983
Anuria 20.25 18.82 21 15779 24320 110549179
Headache 20.20 18.82 62 15738 882315 109691184
Tetany 20.18 18.82 10 15790 3594 110569905
Renal impairment 20.15 18.82 66 15734 188379 110385120
Posthaemorrhagic hydrocephalus 20.03 18.82 4 15796 65 110573434
Toxic skin eruption 19.83 18.82 22 15778 27493 110546006
Quadrantanopia 19.76 18.82 5 15795 244 110573255
Lactic acidosis 19.71 18.82 42 15758 92769 110480730
Altered state of consciousness 19.69 18.82 32 15768 57594 110515905
Rectal haemorrhage 19.68 18.82 49 15751 119784 110453715
Wheezing 19.67 18.82 6 15794 255224 110318275
Acute leukaemia 19.55 18.82 8 15792 1841 110571658
Subdural haemorrhage 19.54 18.82 12 15788 6546 110566953
Haemorrhage 18.99 18.82 45 15755 106647 110466852
Treatment failure 18.84 18.82 8 15792 277226 110296273

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AA07 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Vitamin K antagonists
MeSH PA D000925 Anticoagulants
MeSH PA D006401 Hematologic Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50390 EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor

Related Drugs by ATC class:

B01AA Vitamin K antagonists 9 drugs
clorindionedicoumaroldiphenadioneethyl biscoumacetatefluindionephenindionephenprocoumontioclomarolwarfarin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pulmonary embolism indication 59282003 DOID:9477
Venous thrombosis indication 111293003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.96 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Vitamin K epoxide reductase complex subunit 1 Enzyme INHIBITOR IC50 6.11 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Vitamin K epoxide reductase complex subunit 1 Enzyme INHIBITOR IC50 6.11 IUPHAR

External reference:

IDSource
N0000167009 NUI
D07064 KEGG_DRUG
154 RXNORM
C0000956 UMLSCUI
CHEBI:53766 CHEBI
CHEMBL397420 ChEMBL_ID
DB01418 DRUGBANK_ID
D000074 MESH_DESCRIPTOR_UI
54676537 PUBCHEM_CID
9015 IUPHAR_LIGAND_ID
503 INN_ID
I6WP63U32H UNII
002087 NDDF
387457003 SNOMEDCT_US
79356008 SNOMEDCT_US
I6WP63U32H INXIGHT DRUGS

Pharmaceutical products:

None